Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBGVCannabigerovarin

The propyl-chain homologue of CBG, present in small amounts in cannabis.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₁₉H₂₈O₂

CAS 55824-11-8

Family
PhytocannabinoidMinor
Origin
Decarboxylation
Molar mass
288.40 g/mol

Updated on

In plain terms

CBGV is a "cousin" of CBG whose side chain has three carbons instead of five. It forms in the plant when its acid, CBGVA, loses its carboxyl group. Its effects in humans have not been studied in the sources consulted.

Receptors and activity

Target network

TRPV1Agonistno measured value
  • Activates
  • Blocks or inhibits

The lower the cited value, the closer the target sits to CBGV: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CBGV.

Brain, side view
Body, front view
Blood

TRPV1TRPV1 found in 7 regions of the body

  1. Sensory gangliapresentExpressed in dorsal root ganglia1
  2. Spinal cordpresentNerve fibres in the spinal dorsal horn2
  3. CortexpresentParietal cortex neurons (layers 3 and 5)3
  4. SkinpresentWidely distributed in the skin4
  5. Blood vesselspresentPresent on dermal blood vessels4
  6. BonepresentPresent on osteoclasts5
  7. LiverpresentRNA enriched in the liver6

Map sources

  1. Cortright DN et al. The tissue distribution and functional characterization of human VR1. Biochem Biophys Res Commun, 2001 (new tab)
  2. Facer P et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol, 2007 (new tab)
  3. Mezey E et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A, 2000 (new tab)
  4. Ständer S et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol, 2004 (new tab)
  5. Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
  6. Human Protein Atlas. TRPV1 tissue expression (RNA consensus) (new tab)

Cited values

  1. TRPV1Agonistno measured value cited
  2. TRPV2Agonistno measured value cited
  3. GPR55Antagonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Cannabigerovarin (CBGV) is the neutral CBG-type phytocannabinoid with a propyl (C3) side chain, isolated in 1975 from a Thai "Meao variant" cannabis (Shoyama et al.). It forms by non-enzymatic decarboxylation of CBGVA; the acid, not the neutral form, is the substrate of the synthases of the propyl series. No CB1 or CB2 affinity has been published. In vitro, it activated and desensitised the TRPV1 (human) and TRPV2 (rat) channels, desensitised TRPV3 and TRPV4, and inhibited lysophosphatidylinositol-induced GPR55 signalling. It has also been identified as an impurity of CBG extracted from hemp (Tolomeo et al. 2021).

Key sources.

History

Source
Cannabis sativa L.: present in the plant, formed by non-enzymatic decarboxylation of its acid, CBGVA. It has also been identified, with cannabigerobutol (CBGB), as an impurity of CBG extracted from hemp (Tolomeo et al. 2021).

Biosynthetic pathway

The plant produces cannabigerovarinic acid (CBGVA) from divarinolic acid and geranyl pyrophosphate through a geranyltransferase (Walsh et al. 2021). CBGV derives from it by decarboxylation under heat, light or time. It is CBGVA, not CBGV, that the synthases convert into THCVA and CBDVA, the acid precursors of THCV and CBDV.

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Neutral form: decarboxylation of a plant acid

Chemistry

Type CBG · C3 side chain · neutral form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

Cannabigerovarin (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Shoyama Y. et al. 1975, Chem Pharm Bull 23:1894-1895: cannabichromevarin and cannabigerovarin, two new propyl homologues (new tab)DOI 10.1248/cpb.23.1894
  2. Walsh K.B. et al. 2021, Front Pharmacol 12:777804: biosynthesis of CBGVA and pharmacology of minor cannabinoids (new tab)PMID 34916950
  3. De Petrocellis L. et al. 2011, Br J Pharmacol 163:1479-1494: cannabinoids and TRP channels (CBGV tested) (new tab)PMID 21175579
  4. De Petrocellis L. et al. 2012, Acta Physiol 204:255-266: cannabinoids and TRPV3/TRPV4 channels (new tab)PMID 21726418
  5. Anavi-Goffer S. et al. 2012, J Biol Chem 287:91-104: modulation of LPI/GPR55 signalling by cannabinoids (new tab)PMID 22027819
  6. Tolomeo F. et al. 2021, J Pharm Biomed Anal 203:114215: CBGV and CBGB, impurities in hemp-extracted CBG (new tab)PMID 34153935

Identifiers

Names

Common name
Cannabigerovarin
IUPAC name
2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol
Other names
CBGV

Identifiers

Formula
C₁₉H₂₈O₂
CAS
55824-11-8
PubChem CID
59444407(new tab)
InChIKey
YJYIDZLGVYOPGU-XNTDXEJSSA-N
SMILES
CCCC1=CC(=C(C(=C1)O)C/C=C(\C)/CCC=C(C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.